Table 1

Study methods for included randomised controlled trials

Study nameStudy durationCountryBlindingInterventionComparatorDaily dose of nicergoline (mg)
Arrigo et al714 weeksItalyDouble-blindNicergolinePlacebo60
Battaglia et al86 monthsItalyDouble-blindNicergolinePlacebo60
Battaglia et al96 monthsItalyDouble-blindNicergolineErgot mesylates60
Battaglia et al1012 monthsItalyDouble-blindNicergolinePlacebo60
Bes et al1124 monthsFranceDouble-blindNicergolinePlacebo60
Bossi12ItalyDouble-blindNicergolineBuflomedil8
Brola131 monthPolandSingle-blindNicergolinePentoxifylline30
Cascone et al141 monthItalyDouble-blindNicergolinePlacebo15
Colombeau and Ballanger1515 daysFranceDouble-blindNicergolinePlacebo40
Crook166 monthsUSADouble-blindNicergolinePlacebo60
Dubreuil171 monthFranceDouble-blindNicergolineGBENR
Felisati et al183 monthsItalyDouble-blindNicergolinePlacebo60
Forette et al193 weeksFranceDouble-blindNicergolinePlacebo30
Gessner et al2012 weeksGermanyDouble-blindNicergolineGBE15
Herrmann216 monthsGermanyDouble-blindNicergolinePlacebo60
Kugler and Meurer-Krull226 monthsGermanyDouble-blindNicergolineDihydroergotamine30
Lu2312 weeksChinaDouble-blindNicergolineAniracetam60
Marolda et al2420 daysItalyDouble-blindNicergolineEburnamonine15–20
Materna2512 weeksGermanyDouble-blindNicergolineFlunarizine10–30
Nakashima et al266 monthsJapanDouble-blindNicergolineImidapril15
Nappi et al2712 monthsItalyDouble-blindNicergolinePlacebo60
Nishiyama et al284 weeksJapanOpen-labelNicergolinePlacebo45
Pilkowska et al293 monthsPolandDouble-blindNicergolinePlacebo60
Pogliani 1979303 monthsGermanyDouble-blindNicergolinePlacebo15
Ronchi et al316 daysItalyDouble-blindNicergolinePlacebo
Saletu et al328 weeksAustriaDouble-blindNicergolinePlacebo30–60
Setyopranoto et al33IndonesiaDouble-blindNicergolinePlacebo60
Winblad et al346 monthsEuropeDouble-blindNicergolinePlacebo60
Zucconi and Terzi Bolaffio351 monthItalyDouble-blindNicergolineDihydroergotoxine2 intramuscular
  • GBE, ginkgo biloba extract; NR, not reported.